Climb Bio
CLYM
43 hedge funds and large institutions have $146M invested in Climb Bio in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 19 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
23% more funds holding
Funds holding: 35 → 43 (+8)
0.42% more ownership
Funds ownership: 65.48% → 65.91% (+0.42%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less capital invested
Capital invested by funds: $182M → $146M (-$35.7M)
68% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
+$3.98M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.33M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$824K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$172K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$148K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.91M |
| 2 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$1.39M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$785K |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$679K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$494K |
CLYM Hedge Fund Activity: Q1 2022 in Review
43 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q1 2022, worth a combined $146M — down 20% from $182M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CLYM positions and 3 closed out — a net gain of 8 holders — while 6 added to existing stakes and 19 trimmed.
The largest buyer was Samlyn Capital, adding an estimated $3.98M. The largest seller was JP Morgan Chase, cutting an estimated $1.91M.
- 43 institutional investors held Climb Bio (CLYM) as of Q1 2022, up from 35 in Q4 2021.
- Funds reported $146M of Climb Bio stock for Q1 2022, down 20% quarter-over-quarter.
- 11 funds opened new Climb Bio positions in Q1 2022 and 3 closed out, a net change of +8 holders.
- The largest Climb Bio buyer in Q1 2022 was Samlyn Capital, an estimated $3.98M added.
- The largest Climb Bio seller in Q1 2022 was JP Morgan Chase, an estimated $1.91M sold.
Based on aggregated 13F filings for Q1 2022.